MEN1611

Phase 2Small molecule

Menarini

MEN1611 is one of 80 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Breast CancerActive, not recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Tykerb

GSK

Preclinical

80 5

Adriamycin

GGynecologic Oncology Group

Preclinical

87 6

Avastin

BBio-Thera Solutions

Preclinical

153 7

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 8

Prolia

Amgen

Preclinical

14 9

Gemzar

GGynecologic Oncology Group

DATROWAY

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Breast Cancer

NCT05810870

Clinical

Trials by Indication[1]

Breast Cancer2 trials

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

Completed· Menarini logo

Menarini·Phase 1·NCT03767335·62 enrolled

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

Active, not recruiting·MMedSIR·Phase 2·NCT05810870·14 enrolled

Metastatic Colorectal Cancer1 trial

MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Completed· Menarini logo

Menarini·Phase 1/2·NCT04495621·29 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for MEN1611. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MEN1611 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MEN1611. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Menarini company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Menarini

MEN1611

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Breast Cancer2 trials

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News